v3.26.1
Series C Preferred Stock - Additional Information (Details) - shares
 6 Months Ended
May 18, 2026
Jun. 30, 2026
Dec. 31, 2025
Class of Stock [Line Items]      
Preferred stock, shares authorized (in shares)   10,000,000 10,000,000
Voting Rights   Except as otherwise provided in the Certificate of Designation or as otherwise required by the Delaware General Corporation Law of the State of Delaware, the Series C Preferred Stock has no voting rights and no rights to elect directors.  
Orphai Therapeutics [Member]      
Class of Stock [Line Items]      
No of common stock issued 162,971    
Orphai Therapeutics [Member] | Common Stock      
Class of Stock [Line Items]      
No of common stock issued 162,971    
Convertible preferred stock, shares issued upon conversion 52    
Series C Preferred Stock | Orphai Therapeutics [Member]      
Class of Stock [Line Items]      
Preferred stock, shares authorized (in shares) 294,370    
No of common stock issued 67,101.235    
Stock issued during period shares acquisitions 144,200.633    
Convertible preferred stock, shares issued upon conversion   570,169  
Series C Preferred Stock | Orphai Therapeutics [Member] | Common Stock      
Class of Stock [Line Items]      
Convertible preferred stock, shares issued upon conversion 52